The identification of FOXDs as candidate Wnt pathway activators is consistent with the recent observation that silencing of FOXD1 lowered β-catenin levels in prostate cancer cells and concomitantly decreased cell proliferation and invasion (33). The gene discussed is FOXD1; the disease is prostate cancer.